Literature DB >> 20431550

Pharmacotherapy: How well can we compare different biologic agents for RA?

Josef S Smolen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20431550     DOI： 10.1038/nrrheum.2010.58

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

Review 2.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Authors:  J L Nam; K L Winthrop; R F van Vollenhoven; K Pavelka; G Valesini; E M A Hensor; G Worthy; R Landewé; J S Smolen; P Emery; M H Buch
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

Review 3.  Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Authors:  Cécile Gaujoux-Viala; Josef S Smolen; Robert Landewé; Maxime Dougados; Tore K Kvien; Emilio Martin Mola; Marieke Scholte-Voshaar; Piet van Riel; Laure Gossec
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

4.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

Authors:  R F van Vollenhoven; S Ernestam; P Geborek; I F Petersson; L Cöster; E Waltbrand; A Zickert; J Theander; A Thörner; H Hellström; A Teleman; C Dackhammar; F Akre; K Forslind; L Ljung; R Oding; A Chatzidionysiou; M Wörnert; J Bratt
Journal:  Lancet       Date:  2009-08-08       Impact factor: 79.321

Review 5.  Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.

Authors:  P Emery; F C Breedveld; M Dougados; J R Kalden; M H Schiff; J S Smolen
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

Review 6.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

7.  Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.

Authors:  Monika Schoels; Daniel Aletaha; Josef S Smolen; Johannes W J Bijlsma; Gerd Burmester; Ferdinand C Breedveld; Maurizio Cutolo; Bernard Combe; Maxime Dougados; Paul Emery; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten De Wit
Journal:  Ann Rheum Dis       Date:  2009-04-22       Impact factor: 19.103

Review 8.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Authors:  Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103
  9 in total
  1 in total

Review 1.  Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.

Authors:  Mahboob U Rahman; Jacqui Buchanan; Mittie K Doyle; Elizabeth C Hsia; Timothy Gathany; Shreekant Parasuraman; Daniel Aletaha; Eric L Matteson; Philip G Conaghan; Edward Keystone; Désireé van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2011-06-27       Impact factor: 19.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.